Clinical trials employing vaccination with prostate-specific membrane antigen (PSMA) loaded dendritic cells (DC) in patients (pts) with advanced prostate cancer yielded response rates of >30%. We decided for HLA-A2 restricted peptides derived from prostate stem cell antigen (PSCA) and prostate specific antigen (PSA 1–3) because both antigens are overexpressed in >85% of prostate cancer and were demonstrated to induce antigen specific T-cell responses in vitro. Cell penetrating peptide (CPP) is a peptide derived from the HIV-tat protein that prolongs antigen presentation in vitro leading to enhanced antitumor immunity in vivo. Therefore, half of the pts were assigned to receive CPP-PSCA loaded DCs. The purpose of this study is to assess feasibility, patient safety, PSCA-/PSA-specific T-cell responses and tumor regression in vivo. Pts were vaccinated s.c. in 14d intervals. Response was assessed two weeks after the 4th vaccination. Delayed-type hypersensitivity (DTH) was tested d4+d46. Immune competence was monitored by HBV vaccination d1+d43. So far, 9/12 planned pts completed vaccination. No toxicities were observed. 5/9 pts achieved SD (3 with <50% decrease, 2 with <50% increase in PSA) and 3 of these but no non-responders developed a positive DTH after the 4th vaccination. The addition of CPP did not correlate with outcome. Responding pts received at mean two further vaccinations 4 weeks apart. At a median follow-up of 8.6 months 70% of pts are alive compared to a reported OS of 59% and 28% at a follow-up of 6 and 11 months, respectively for pts with metastatic, hormone-refractory disease [1–3]. No peptide specific T-cells were detected in two pts evaluated so far, however, the correlation of clinical and DTH responses suggests a tumor specific immunity. Our data indicate that vaccination with PSA/PSCA-peptide-loaded, autologous DCs is safe and well tolerated. Vaccination of more patients, long-term follow-up and completion of immune monitoring are needed to evaluate anti tumor effects.
References
Fossa SD: Br J Urol. 1992, 69: 175-179.
Kelly WK: J Clin Oncol. 1993, 11: 607-615.
Smaletz O: J Clin Oncol. 2002, 20: 3972-3982. 10.1200/JCO.2002.11.021.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Kaskel, A., Zeiser, R., Jochim, R. et al. Transitory response to vaccination with PSCA-/PSA-peptide loaded, autologous dendritic cells in patients with metastatic, hormone-refractory prostate cancer. Cancer Cell Int 4 (Suppl 1), S16 (2004). https://doi.org/10.1186/1475-2867-4-S1-S16
Received:
Published:
DOI: https://doi.org/10.1186/1475-2867-4-S1-S16